3/24/2023 0 Comments Ancora bioTeneobio spun out three additional companies prior to closing its deal with Amgen, however. ![]() Amgen followed a month later with a deal for Teneobio itself. Since then, AbbVie bought a Teneobio affiliate called TeneoOne for a multiple myeloma drug the two had been developing. Prior to 2021, the biotech had parlayed drugmakers’ growing interest in bispecific medicines into a list of partners including AbbVie, Johnson & Johnson, Gilead’s Kite Pharma division and gene editing biotech Intellia Therapeutics. The acquisition, meanwhile, is the third so far of an entity originally named Teneobio, a privately-held Californian biotech specializing in dual-acting antibody drugs. Amgen’s marketed leukemia drug Blincyto works similarly, though Younes noted that TNB-486 was designed “to optimize the therapeutic window of T-cell activation,” a reference to the range of doses that might be effective without substantial side effects. The medicine binds to CD19, a target on B cells, as well as a T cell receptor called CD3. The company believes TeneoTwo’s drug, used either alone or in combination with other agents, could help “deepen clinical responses and improve patient outcomes” in B-cell malignancies, Anas Younes, its senior vice president of hematology R&D, said in a statement. With Monday’s deal, AstraZeneca is now in the mix too. Treatments from Roche, partners AbbVie and Genmab as well as Johnson & Johnson, among others, are in advanced stages of clinical testing. In blood cancer, for instance, dual-acting cancer medicines may become more convenient alternatives to the personalized, logistically complex cell therapies sold by Novartis, Gilead and Bristol Myers Squibb. Dual-acting antibody drugs for cancer, hemophilia and a form of vision loss are now on the market and several for lymphoma, multiple myeloma and other malignancies could follow. ![]() Bispecific antibodies, which simultaneously latch onto antigens on two different cells, have drawn considerable interest from large drugmakers in recent years.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |